Covered recipient · General Payments record
JACK RUBIO
Allopathic & Osteopathic Physicians Internal Medicine Nephrology
General Payments · PY2018–2024
$71,748.72
- Reported across 154 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Long term medical supply or device loan | $7,000.00 | 1 |
| Food and Beverage | $330.49 | 14 |
| Education | $24.61 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AngioDynamics, Inc. | $7,000.00 | 1 |
| Ardelyx, Inc. | $189.82 | 8 |
| Novo Nordisk AS | $80.42 | 4 |
| Relypsa, Inc. | $30.34 | 1 |
| Otsuka America Pharmaceutical, Inc. | $29.91 | 1 |
| AKEBIA THERAPEUTICS INC | $24.61 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AKEBIA THERAPEUTICS INC | $24.61 | 09/18/2024 | Education | Undisputed | 01/23/2026 | 1145833257 | CMS |
| AngioDynamics, Inc. | $7,000.00 | 06/19/2024 | Long term medical supply or device loan | Undisputed | 01/23/2026 | 1093158591 | CMS |
| Ardelyx, Inc. | $119.51 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146704880 | CMS |
| Ardelyx, Inc. | $9.65 | 03/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146704882 | CMS |
| Ardelyx, Inc. | $9.53 | 05/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146704884 | CMS |
| Ardelyx, Inc. | $4.45 | 05/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146704886 | CMS |
| Ardelyx, Inc. | $7.95 | 07/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146704888 | CMS |
| Ardelyx, Inc. | $17.70 | 08/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146704890 | CMS |
| Ardelyx, Inc. | $7.43 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146704892 | CMS |
| Ardelyx, Inc. | $13.60 | 11/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146704894 | CMS |
| Novo Nordisk Inc | $18.53 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096997907 | CMS |
| Novo Nordisk Inc | $19.01 | 08/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096889756 | CMS |
| Novo Nordisk Inc | $20.17 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097674177 | CMS |
| Novo Nordisk Inc | $22.71 | 12/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097624933 | CMS |
| Otsuka America Pharmaceutical, Inc. | $29.91 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118973020 | CMS |
| Vifor Pharma, Inc. | $30.34 | 03/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124035769 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.